Listing 1 - 10 of 11 | << page >> |
Sort by
|
Choose an application
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients’ quality of life.
aflibercept monotherapy --- polypoidal choroidal vasculopathy --- neovascular age-related macular degeneration --- good baseline visual acuity --- ForeseeHome AMD Monitoring System® --- AREDS2-HOME study --- age-related macular degeneration --- exudation --- optical coherence tomography angiography --- anti-vascular endothelial growth factor --- brolucizumab --- epithelial tear --- optical coherence tomography --- Sorsby’s fundus dystrophy --- Sorsby --- hereditary retinal dystrophy --- choroidal neovascularisation --- macular neovascularization --- anti-VEGF treatment --- long-term FU --- treatment outcome --- emerging treatment --- neovascular age-related macular degeneration (nAMD) --- Vascular Endothelial Growth Factor (VEGF) --- cataract surgery --- clinical trials --- real-world evidence --- AMD --- oct-angiography --- fellow eye --- choriocapillaris --- quiescent macular neovascularization --- ranibizumab --- aflibercept --- anti-VEGF --- visual acuity --- reading acuity --- disease activity --- treatment change --- treat and extend --- switch therapy --- retina --- choroidal neovascularization --- angiogenesis --- meteorin --- therapeutic innovation --- prevention --- nutrients --- lifestyle --- treatment-naive --- anti–vascular endothelial growth factor --- cardiovascular risk factors --- arterial hypertension --- macula-off rhegmatogenous detachment --- superficial perifoveal capillary plexus --- retinal deep perifoveal capillary plexus --- identification --- risk --- Delphi --- STARS® --- food supplement --- bevacizumab --- meta-analysis --- meta-regression --- n/a --- age-related macular degeneration (AMD) --- comparative therapies --- effectiveness --- intravitreal anti-vascular endothelial growth factor --- treat-and-extend --- pro re nata regimen --- Sorsby's fundus dystrophy
Choose an application
Dear Colleagues, The brain is vulnerable to injury. Following injury in the brain, apoptosis or necrosis may occur easily, leading to various functional disabilities. Neuronal death is associated with a number of neurological disorders including hypoxic ischemia, epileptic seizures, and neurodegenerative diseases. The brain subjected to injury is regarded to be responsible for the alterations in neurotransmission processes, resulting in functional changes. Oxidative stress produced by reactive oxygen species has been shown to be related to the death of neurons in traumatic injury, stroke, and neurodegenerative diseases. Therefore, scavenging or decreasing free radicals may be crucial for preventing neural tissues from harmful adversities in the brain. Neurotrophic factors, bioactive compounds, dietary nutrients, or cell engineering may ameliorate the pathological processes related to neuronal death or neurodegeneration and appear beneficial for improving neuroprotection. As a result of neuronal death or neuroprotection, the brain undergoes activity-dependent long-lasting changes in synaptic transmission, which is also known as functional plasticity. Neuroprotection implying the rescue from neuronal death is now becoming one of global health concerns. This Special Issue attempts to explore the recent advances in neuroprotection related to the brain. This Special Issue welcomes original research or review papers demonstrating the mechanisms of neuroprotection against brain injury using in vivo or in vitro models of animals as well as in clinical settings. The issues in a paper should be supported by sufficient data or evidence. Prof. Bae Hwan Lee Guest Editor
global cerebral ischemia --- amiloride --- sodium–hydrogen exchanger-1 --- zinc --- neuronal death --- neuroprotection --- neurodegenerative disorder --- choline acetyltransferase (ChAT) --- trimethyltin (TMT) --- bean phosphatidylserine (Bean-PS) --- brain-derived neurotrophic factor --- moderate hypoxia --- physical exercise --- psychomotor function --- reaction time --- cortisol --- catecholamines --- nitrite --- endotheline-1 --- lactate --- pyridoxine deficiency --- ischemia --- gerbil --- homocysteine --- cell death --- glia --- neurogenesis --- N-acetyl-l-cysteine --- transient receptor potential melastatin 2 --- neurodegeneration --- Alzheimer’s disease --- metabolic disease --- adiponectin --- insulin --- antioxidants --- stroke --- preventive gene therapy --- adenoviral vector --- VEGF --- GDNF --- NCAM --- human umbilical cord blood mononuclear cells --- antioxidant --- brain --- neurodegenerative disease --- oxidative stress --- PGC-1α --- vascular endothelial growth factor --- vascular endothelial growth factor receptor 2 --- PI3K/AKT --- MEK/ERK --- status epilepticus --- hippocampus --- middle cerebral artery occlusion --- reperfusion injury --- lipid emulsion --- excitotoxicity --- apoptosis --- GPR4 receptor --- MPP+ --- Parkinson’s disease --- CRISPR/cas9 --- ischemic stroke --- blood brain barrier --- nanoparticle-based drug delivery --- brain targeting --- BDNF --- miRNAs --- synaptic plasticity --- depression --- glioblastoma --- astrocytes --- astrocytic networks --- connexin 43 --- calcium activity --- neural injury --- nimodipine --- subarachnoid haemorrhage --- acid-sensing ion channels --- oxygen-glucose deprivation --- liver growth factor --- inflammation --- microglia --- Tg2576 transgenic mice --- amyloid-beta --- oculomotor system --- trophic factors --- motoneurons --- axotomy --- amyotrophic lateral sclerosis --- electroneutral transport --- cation-chloride cotransporters --- KCCs --- NKCCs --- WNK-SPAK/OSR1 --- ascorbic acid --- aging --- organotypic hippocampal slice culture --- n/a --- sodium-hydrogen exchanger-1 --- Alzheimer's disease --- Parkinson's disease
Choose an application
Marine herbal medicine generally refers to the use of marine plants as original materials to develop crude drugs, or for other medical purposes. The term ‘marine plants’ usually denotes macroalgae grown between intertidal and subintertidal zones, including Chlorophyta, Phaeophyta, and Rhodophyta. Considerable progress has been made in the field of biomedical research into marine microalgae and microorganisms in the past decade. As the most important source of fundamental products in the world, marine plants have a very important role in biomedical research. Furthermore, worldwide studies have consistently demonstrated that many crude drugs derived from marine plants contain novel ingredients that may benefit health or can be used in the treatment of diseases; some have been developed into health foods, and some even into drugs. It is expected that there are many substances of marine plant origin that will have medical applications in terms of improving human health and are awaiting discovery.
marine functional foods --- vascular endothelial growth factor receptor-3 --- ultrafiltration --- lung fibrosis --- metabolic instability --- peptide fractions --- cembrane --- 3T3 fibroblasts --- Pinnigorgia sp. --- lymphatic endothelial cells --- bile salts --- caspase-3 --- cytokine --- hepatic stellate cells --- macrophage --- oral squamous cell carcinoma --- anti-inflammation --- MAPK --- fucoidan --- Jaspine B --- ACE-inhibition --- bioactivity --- sulfated galactan --- bioavailability --- ROS --- anti-angiogenesis --- briarellin --- neolignan --- radiation pneumonitis --- Pachyclavularia --- Lumnitzera racemosa --- apoptosis --- phomaketide A --- prodigiosin --- neutrophil --- intestinal permeability --- autophage --- secosterol --- octocoral --- amino acids composition --- phlorotannins --- cardiovascular-health --- antioxidant properties --- marine viva --- green seaweed --- protein enzymatic hydrolysate --- lymphangiogenesis --- edible brown algae --- briarane --- Herbs --- Marine pharmacology. --- Marine algae --- Therapeutic use. --- Sea vegetables --- Seaweed --- Seaweeds --- Vegetables, Sea --- Algae --- Marine plants --- Drugs from the sea --- Marine pharmacognosy --- Materia medica, Marine --- Marine biology --- Materia medica --- Pharmacognosy --- Herb remedies --- Herbal medicine --- Medicinal herbs
Choose an application
Blindness and visual impairment impact significantly on an individual’s physical and mental well-being. Loss of vision is a global health problem, with approximately 250 million of the world’s population currently living with vision loss, of which 36 million are classified as blind. Visual impairment is more frequent in the elderly, with cataract and age-related macular degeneration (AMD) accounting for over 50% of cases globally. Oxidative stress has been strongly implicated in the pathogenesis of both conditions, and consequently the role of nutritional factors, in particular carotenoids and micronutrient antioxidants, have been investigated as possible preventative or therapeutic strategies. Dry eye syndrome (DES) is one of the most common ophthalmic conditions in the world. DES occurs where the eye does not produce enough tears and/or the tears evaporate too quicklyleading to discomfort and varying degrees of visual disturbance. There has recently been a great deal of interest in the potential for oral or topical supplementation with essential fatty acids (EFAs), specifically omega-3 and omega-6 fatty acids, as an adjunct to conventional treatments for DES. The objective of this Special Issue on ‘Nutrition and Eye Health’ is to publish papers describing the role of nutrition in maintaining eye health and the use of nutritional interventions to prevent or treat ocular disease. A particular (but not exclusive) emphasis will be on papers (reviews and/or clinical or experimental studies) relating to cataract, AMD and DES.
polyphenols --- n/a --- crocin --- chyrsin --- glaucoma --- dietary assessment --- photoreceptor degeneration --- dry eye --- RR-zeaxanthin --- nutritional supplements --- drug discovery --- corneal neovascularization (CNV) --- AMD --- dietary antioxidants --- micronutrients --- age-related macular degeneration --- preclinical models --- lenses --- microvascular lesions --- cyclooxigenase-2 (COX-2) --- angiogenesis --- fish oil --- macrophage --- anti-oxidant --- vascular endothelial growth factor (VEGF) --- rosmarinic acid --- visual cycle --- diabetic retinopathy --- lutein --- gut-retina axis --- light damage --- crocetin --- supplements --- clinical practice guidelines --- nutrition --- light --- eye disease --- dietary habits --- flavonoids --- phytoconstituents --- saffron --- carotenoids --- fatty acid --- electroretinography --- lens --- advanced glycation end products --- interleukin-1? (IL-1?) --- mesozeaxanthin (RS zeaxanthin) --- endoplasmic reticulum stress --- omega-3 polyunsaturated fatty acids --- clinical survey --- corneal chemical burn --- reduced glutathione --- omega-3 --- AGREE II --- retina --- inflammation --- anti-inflammatory --- retinal pigment epithelium --- diet --- Lactobacillus paracasei KW3110 --- Crocus Sativus L. --- saponins --- cataract --- CODS --- neoangiogenesis --- estrogen-deficient rats --- food frequency questionnaire --- gut microbiota --- antioxidant supplements --- sinapic acid --- personalised medicine --- systematic reviews --- nuclear factor-kappaB (NF-?B) --- diabetes --- Cucurbita argyrosperma --- oxidative stress --- endoplasmic reticulum
Choose an application
This reprint includes contributions from leaders in the field of personalized medicine in ophthalmology. The contributions are diverse and cover pre-clinical and clinical topics. We hope you enjoy reading the articles.
subthreshold micropulse laser --- 577-nm laser --- laser fixed parameters --- diabetic retinopathy --- diabetic macular edema --- optical coherence tomography --- autofluorescence --- real-life --- diabetic macular oedema --- visual prognosis --- indicators --- personalized medicine --- age-related macular degeneration --- choroidal neovascularization --- classification --- machine learning --- type 2 diabetes --- retinopathy --- ethnicity --- general practice --- risk factors --- progression --- glycemic gap --- glucose variability --- ETDRS classification --- biomarkers --- phenotypes --- anti-vascular endothelial growth factor --- diabetic retinopathy severity scale --- panretinal leakage index --- neovascular age-related macular degeneration --- anti-VEGF therapy --- retinal thickness --- visual acuity --- variability --- leakage index --- microaneurysms --- intravitreal aflibercept --- neovascularization --- ultra-widefield fluorescein angiography --- retinal imaging --- quantitative biomarkers --- precision medicine --- autoantibodies --- AT1-receptor --- PAR1 --- VEGF-A --- VEGF-B --- VEGF-receptor 2 --- AMD --- complement system --- semi-quantitative multiplex profilin --- mass spectrometry --- C4 --- vitronectin --- factor I --- genetic variants --- metabolites --- HDL --- central area thickness --- biomarker --- microRNA --- anti-VEGF --- retina --- edema --- OCT --- tomography --- microphysiological systems --- blood-neural barriers --- neurovascular unit --- disease modeling --- 3D models --- organ-on-a-chip --- inner blood-retinal barrier --- n/a
Choose an application
It is well known that pregnancy complications, including preeclampsia, preterm birth, stillbirth, and intrauterine growth restriction affect over 12% of all pregnancies worldwide. These complications negatively impact both maternal and neonatal health and have short- and long-term effects such as an increased risk of neurodevelopmental and cardiovascular diseases. Over the past decade, numerous groups have investigated the use of new and/or existing drugs to either prolong gestation, such as in cases of threatened preterm labour; alleviate hypertension in preeclampsia; or promote adequate blood flow and nutrient delivery to the placenta to facilitate growth in IUGR. The overarching goal has been to promote healthier pregnancies and neonatal health, but it has been difficult to translate this work into the clinical setting, with problems in terms of drug delivery, specificity, and importantly, the early diagnostic capacities for complications in pregnancy. This book focuses on the early detection, potential novel therapeutic targets, risk factors, maternal outcomes, and long-term consequences of this critical problem.
ultrasonography --- elastography --- uterine cervix --- term pregnancy --- parturition --- genotyping --- preeclampsia --- MMP-9 --- MMP-2 --- SNPs --- tocolytic --- preterm birth --- preterm labor --- neonate --- prematurity --- pregnancy --- therapeutic --- progesterone --- fetus --- sex as a biological variable --- sex differences --- pregnancy complications --- placenta --- prenatal diagnosis --- fetal growth restriction --- miscarriage --- chorio-deciduitis --- grade --- amnionitis --- acute histologic chorioamnionitis --- intra-amniotic inflammatory response --- beta-blocker --- endothelial dysfunction --- cardiovascular disease --- pregnancy loss --- immunology --- vascular endothelial growth factor --- galectin-9 --- interleukin-4 --- proteomics --- urine --- biomarkers --- IBP4 --- SHBG --- RPL --- NK cells --- sildenafil --- PDE5A --- VEGF-A --- angiotensin --- infant --- newborn --- female --- abruptio placentae --- Apgar score --- pregnant women --- gestational age --- IL-1 blockade --- anakinra --- canakinumab --- human --- inflammation --- fetal growth restriction (FGR) --- intra-uterine growth restriction (IUGR) --- SPINT1 --- HAI-1 --- stillbirth --- placental insufficiency --- histopathology --- cardiovascular risk --- postpartum screening --- n/a
Choose an application
This book is a compilation of articles that brings together current knowledge from an international team of contributors who are dedicated investigators exploring novel strategies for the treatment of glioblastoma. These articles describe some of the latest concepts that will provide students, researchers and clinicians with an overview of the therapeutic approaches being developed in the field of neuro-oncology to combat this deadly disease.
glioblastoma --- glioma --- temozolomide --- radiotherapy --- immunotherapy --- novel therapy --- personalized treatment --- drug repurposing --- invasion --- invadopodia --- ion channels --- gene therapy --- viral vectors --- brain tumor --- nanomedicine --- cancer stem cell --- targeted therapy --- brain cancer --- cell cycle --- differentiation --- proliferation --- RAS --- SRGAP2 --- stem cell --- TP53 --- glioblastoma multiforme --- GBM --- nerve/glial antigen 2 --- NG2 --- CK2 --- CX-4945 --- migration --- CRISPR/Cas9 --- anticancer --- anti-angiogenesis --- thyrointegrin αvβ3 --- PEG --- triazole tetrac --- P-bi-TAT --- P-m-TAT --- tetrac --- one-carbon metabolism --- de novo purine synthesis --- metabolic reprogramming --- metabolic treatment --- vaccine --- immune checkpoint inhibitors --- chimeric antigen receptor (CAR) T cells --- glioblastoma (GB) --- prolyl-oligopeptidase (POP) --- vascular endothelial growth factor (VEGF) --- transforming growth factor-β (TGF-β) --- angiopoietin (Ang) --- endothelial nitric oxide synthase (eNOS) --- newly diagnosed glioblastoma --- recurrent glioblastoma --- new trial design --- drug-inducible gene expression --- Mardepodect --- Regorafenib --- drug targets --- tumor antigens --- renin–angiotensin system --- pluripotent stem cells --- organoids --- cancer stem cells --- cancer stem cell niche --- tumor microenvironment --- n/a --- renin-angiotensin system
Choose an application
There are 12 papers published with 8 research articles, 3 review articles and 1 perspective. The topics cover: Biomedical microfluidics Lab-on-a-chip Miniaturized systems for chemistry and life science (MicroTAS) Biosensor development and characteristics Imaging and other detection technologies Imaging and signal processing Point-of-care testing microdevices Food and water quality testing and control We hope this collection could promote the development of microfluidics and point-of-care testing (POCT) devices for biosensing.
amine functionalization --- graphene oxide --- immunosensor --- electrochemistry --- ferritin --- microfluidics --- synthesis --- nanoparticles --- microparticles --- integrated systems --- modularisation --- HFF-QCM (high fundamental frequency quartz crystal microbalance) --- mass transport --- flow cell --- biosensor --- food safety --- PoC (point of care) --- MQCM (monolithic quartz crystal microbalance) --- wearable biosensors --- biomedical microfluidics --- healthcare monitoring --- sports analytics --- microfluidic adsorption-based sensor --- stochastic model --- adsorption --- mass transfer --- ultimate noise performance --- detection limit --- quantification limit --- fluorescence-linked immunosorbent assay --- lab-on-a-disk --- vascular endothelial growth factor --- 3D microstructure --- high-frequency dielectrophoresis --- glioblastoma cells --- single cell manipulation --- microfluidic point-of-care device --- cancer stem cells --- microstructure topography --- PC12 cells --- neural differentiation --- capillary pressure control valve (CPCV) --- passive valve --- two-phase biocatalysis --- microfluidic droplets --- enzyme --- dental practice --- point-of-care diagnostics --- treatment monitoring --- oral health --- periodontitis --- caries --- saliva diagnostics --- Mycoplasma pneumoniae --- macrolides --- resistance mutations --- microfluidic --- 3D-printed --- sample-to-answer --- qPCR
Choose an application
Biosensors, i.e., devices where biological molecules or bio(mimetic)structures are intimately coupled to a chemo/physical transducer for converting a biorecognition event into a measurable signal, have recently gained a wide (if not huge) academic and practical interest for the multitude of their applications in analysis, especially in the field of bioanalysis, medical diagnostics, and clinical assays. Indeed, thanks to their very simple use (permitting sometimes their application at home), the minimal sample pretreatment requirement, the higher selectivity, and sensitivity, biosensors are an essential tool in the detection and monitoring of a wide range of medical conditions from glycemia to Alzheimer’s disease as well as in the monitoring of drug responses. Soon, we expect that their importance and use in clinical diagnostics will expand rapidly so as to be of critical importance to public health in the coming years. This Special Issue would like to focus on recent research and development in the field of biosensors as analytical tools for clinical assays and medical diagnostics.
molecularly imprinted polymers (MIPs) --- surface imprinted polymers (SIPs) --- electrochemical biosensor --- biomarkers for infectious diseases --- choline biosensor --- amperometric detection --- overoxidized polypyrrole film --- phospholipase D assay --- phosphatidylcholine --- human epididymis protein 4 --- competitive electrochemical immunosensor --- WiFi portable potentiostat --- on-board calibration --- Internet of Things --- 1-methoxy-5-ethyl phenazinium ethyl sulfate --- disposable enzyme sensor --- lactate oxidase --- glucose dehydrogenase --- fructosyl peptide oxidase --- electrochemical enzyme sensor --- biomedical engineering --- surface plasmon resonance --- biosensors --- bio-functionalization optimization --- cost-effective biosensors --- lab-on-a-chip --- aptamer --- labeling --- enzyme --- zinc finger protein --- electrochemical sensor --- vascular endothelial growth factor --- breast cancer --- nanobiosensors --- biomarkers --- electrochemistry --- impedance --- immobilization --- nanomaterial --- nanoparticles (NPs) --- magnetic NPs --- self-assembled monolayers (SAMs) --- signal amplification --- optogenetics --- micro-electrode array --- in situ detection --- electrophysiology --- neural circuit recognition --- biosensor --- carbon dots --- norepinephrine --- tyrosinase --- voltammetry --- folic acid --- real samples --- analytical methods --- electrochemical tools --- choline analysis --- phosphocholine analysis --- choline oxidase --- alkaline phosphatase --- enzyme immobilization --- overoxidized polypyrrole --- electropolymerized non-conducting polymer --- dual electrode biosensor --- simultaneous determination --- flow injection analysis --- capacitive sensing --- alternating current electrokinetic effects --- miRNA sensing --- point-of-care diagnostics
Choose an application
Hereditary hemorrhagic telangiectasia (HHT) is an inherited disease that affects the blood vessels, and is characterized by direct connections between arteries and veins with no intervening capillaries. These abnormal vessels may appear in the skin as tiny red dilated blood vessels in the mouth, lips, fingers and toes. The presence of these vascular lesions in the mucosa can lead to spontaneous and recurrent nose bleeding, typically beginning in mid-childhood, and this is the most common clinical manifestation of HHT, occurring in over 90% of patients. Gastrointestinal bleeding, derived from mucocutaneous vascular lesions, affects approximately 25% of patients, almost always presenting after the age of 50. Chronic nasal and gastrointestinal bleeding can cause iron-deficiency anemia, and current therapeutic strategies are trying to minimize iron and blood transfusions. HHT patients also present large vascular lesions, known as arteriovenous malformations, that occur in internal organs like lungs, liver, and brain, and may result in life-threatening complications often related to the shunting of blood. This book not only highlights the current knowledge regarding diagnosis and treatment of HHT, but also the newest insights in the molecular basis of HHT, the understanding of which is essential for the development of new medicines or therapeutic strategies.
hereditary hemorrhagic telangiectasia --- rare diseases --- telangiectasis --- transforming growth factor-beta (TGF-β) --- Smad pathway --- gastrointestinal bleeding --- epistaxis --- nosebleeds --- tacrolimus --- nasal ointment --- genetic disease --- rare disease --- hereditary hemorrhagic telangiectasia (HHT) --- telangiectases --- mechanical damage --- sun-induced trauma --- vascular malformations --- Endoglin --- activin-receptor-like kinase 1 --- Hereditary Hemorrhagic Telangiectasia --- antithrombotic therapy --- anticoagulants --- antiplatelets --- bleeding --- safety --- HHT --- ALK1 --- endoglin --- raloxifene --- bazedoxifene --- tranexamic acid --- propranolol --- FK506 --- etamsylate --- N-acetylcysteine --- pulmonary arteriovenous malformations --- transcatheter embolotherapy --- screening --- guidelines --- Hereditary hemorrhagic telangiectasia --- pediatrics --- genotype–phenotype correlation --- arteriovenous malformation --- ENG --- ACVRL1 --- SMAD4 --- microRNA --- biomarker --- plasma --- arteriovenous malformations (AVMs) --- angiogenesis --- activin receptor-like kinase 1 (ALK1) --- transforming growth factor beta (TGF-β) --- bone morphogenetic protein (BMP) --- propranolol gel --- epistaxis severity score --- nasal endoscopy --- antiangiogenic properties --- non-coding RNAs --- microRNAs --- long non-coding RNAs --- biomarkers --- endothelial cells --- hereditary hemorrhagic telangiectasia (HHT), second-hit --- arteriovenous malformation (AVM) --- Smad4 --- inflammation --- shear stress --- vascular injury --- somatic mutation --- cell adhesion --- vascular endothelial growth factor (VEGF) --- telangiectasia --- hereditary hemorrhagic --- survival --- life expectancy --- pulmonary arteriovenous malformation --- contrast enhanced magnetic resonance angiography --- liver --- MRI --- ultrasound --- AVM --- bevacizumab --- Osler–Weber–Rendu --- hereditary hemorrhagic telangiectasia/HHT/osler’s disease --- cerebral ischemic lesions --- catheter based embolization therapy
Listing 1 - 10 of 11 | << page >> |
Sort by
|